irasia.com - Investor Relations Asia Pacific
HOME

CSPC Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)

Announcements & Notices       


Please download the latest "Acrobat Reader" to view the PDF.

  • 2024-June-12
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-June-11
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-June-7
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-June-4
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-June-3
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-June-3
  • VOLUNTARY ANNOUNCEMENT - OLAPARIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2024-May-31
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-May-30
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-May-29
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2024-May-28
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2024-May-28
  • RETIREMENT OF EXECUTIVE DIRECTORS, APPOINTMENT OF EXECUTIVE DIRECTORS AND CHANGE OF AUTHORISED REPRESENTATIVE (in PDF)
  • 2024-May-28
  • POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 MAY 2024 (in PDF)
  • 2024-May-27
  • QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024 (in PDF)
  • 2024-May-21
  • VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE RULES OF THE RESTRICTED SHARE AWARD SCHEME (in PDF)
  • 2024-May-17
  • VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2024-May-14
  • DATE OF BOARD MEETING (in PDF)
  • 2024-May-14
  • VOLUNTARY ANNOUNCEMENT - PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2024-April-26
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-April-26
  • VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
  • 2024-April-25
  • NOTICE OF ANNUAL GENERAL MEETING (in PDF)
  • 2024-April-24
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-April-23
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2024-April-22
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024 (in PDF)
  • 2024-April-22
  • GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY (in PDF)
  • 2024-April-19
  • CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MASTER SALES AGREEMENT (in PDF)
  • 2024-April-15
  • EXERCISE OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME (in PDF)
  • 2024-March-25
  • VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2024-March-22
  • VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2024-March-20
  • VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2024-March-20
  • CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER (in PDF)
  • 2024-March-20
  • ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
  • 2024-March-18
  • VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2024-March-14
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
  • 2024-March-8
  • DATE OF BOARD MEETING (in PDF)
  • 2024-February-5
  • VOLUNTARY ANNOUNCEMENT - INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL (in PDF)
  • 2024-January-24
  • KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023 (in PDF)
  • 2024-January-15
  • VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
  • 2023
  • 2023 Announcements & Notices
  • 2022
  • 2022 Announcements & Notices
  • 2021
  • 2021 Announcements & Notices
  • 2020
  • 2020 Announcements & Notices
  • 2019
  • 2019 Announcements & Notices
  • 2018
  • 2018 Announcements & Notices
  • 2017
  • 2017 Announcements & Notices
  • 2016
  • 2016 Announcements & Notices
  • 2015
  • 2015 Announcements & Notices
  • 2014
  • 2014 Announcements & Notices
  • 2013
  • 2013 Announcements & Notices
  • 2012
  • 2012 Announcements & Notices
  • 2011
  • 2011 Announcements & Notices
  • 2010
  • 2010 Announcements & Notices
  • 2009
  • 2009 Announcements & Notices
  • 2008
  • 2008 Announcements & Notices
  • 2007
  • 2007 Announcements & Notices
  • 2006
  • 2006 Announcements & Notices


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Privacy Policy Statement   |   Disclaimer
    © Copyright 1996-2024 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.
    Cookie Policy

    This website uses cookies. Please refer to our Cookie Notice and Privacy Notice for further information. By continuing to use this website, you agree to our use of cookies.

    Close